HC Wainwright Expects Increased Earnings for TG Therapeutics

TG Therapeutics, Inc. (NASDAQ:TGTX) – Analysts at HC Wainwright lifted their FY2025 earnings per share (EPS) estimates for TG Therapeutics in a research note issued to investors on Wednesday, January 15th. HC Wainwright analyst E. White now expects that the biopharmaceutical company will earn $1.26 per share for the year, up from their prior forecast of $1.17. HC Wainwright has a “Buy” rating and a $55.00 price objective on the stock. The consensus estimate for TG Therapeutics’ current full-year earnings is $0.07 per share.

TGTX has been the subject of several other research reports. TD Cowen started coverage on shares of TG Therapeutics in a report on Tuesday, October 29th. They issued a “buy” rating and a $50.00 target price for the company. StockNews.com raised TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, January 7th. The Goldman Sachs Group increased their target price on TG Therapeutics from $20.00 to $22.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Finally, JPMorgan Chase & Co. boosted their price target on TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a report on Monday, November 25th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $40.67.

TG Therapeutics Stock Performance

Shares of NASDAQ TGTX opened at $29.14 on Thursday. The stock has a market cap of $4.54 billion, a PE ratio of -291.37 and a beta of 2.24. TG Therapeutics has a 1 year low of $12.84 and a 1 year high of $36.84. The firm has a fifty day moving average price of $31.69 and a 200-day moving average price of $25.63. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91.

TG Therapeutics (NASDAQ:TGTX) last released its earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.01). TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The firm had revenue of $83.90 million during the quarter, compared to analysts’ expectations of $81.68 million. During the same period in the prior year, the company posted $0.73 earnings per share. The company’s revenue was down 49.4% compared to the same quarter last year.

Institutional Trading of TG Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. State Street Corp increased its position in TG Therapeutics by 35.8% during the third quarter. State Street Corp now owns 9,094,158 shares of the biopharmaceutical company’s stock valued at $212,712,000 after acquiring an additional 2,398,015 shares during the last quarter. Marshall Wace LLP bought a new position in TG Therapeutics during the 2nd quarter valued at about $36,501,000. Principal Financial Group Inc. grew its holdings in TG Therapeutics by 1,549.4% during the 3rd quarter. Principal Financial Group Inc. now owns 772,188 shares of the biopharmaceutical company’s stock valued at $18,061,000 after purchasing an additional 725,371 shares during the last quarter. Point72 Asset Management L.P. purchased a new stake in TG Therapeutics in the 2nd quarter worth about $10,423,000. Finally, Public Sector Pension Investment Board bought a new stake in TG Therapeutics in the third quarter worth about $6,619,000. Hedge funds and other institutional investors own 58.58% of the company’s stock.

Insiders Place Their Bets

In other TG Therapeutics news, Director Sagar Lonial sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $30.44, for a total transaction of $152,200.00. Following the sale, the director now directly owns 100,195 shares in the company, valued at $3,049,935.80. This represents a 4.75 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Sean A. Power sold 11,337 shares of TG Therapeutics stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $30.29, for a total value of $343,397.73. Following the completion of the transaction, the chief financial officer now owns 670,632 shares of the company’s stock, valued at approximately $20,313,443.28. This trade represents a 1.66 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 26,358 shares of company stock valued at $781,497 in the last three months. Corporate insiders own 10.50% of the company’s stock.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.